Topics

Companies Related to "A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations" [Most Relevant Company Matches] RSS

02:46 EST 24th February 2020 | BioPortfolio

Here are the most relevant search results for "A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations" found in our extensive corporate database of over 50,000 company records.

Showing "Study AL101 Patients With Adenoid Cystic Carcinoma Bearing" Companies 1–25 of 4,600+

Extremely Relevant

Ayala Pharmaceuticals, Inc.

Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL...


Relevant

Intracel

Intracel is a leading commercial-stage biotechnology company focused on the development of immune therapy to treat cancer. The company’s pipeline includes product development programs in active immunotherapy and fully human monoclonal antibodies. Intracel has completed clinical studies in Colon, Renal and Ovarian carcinoma, as well as Melanoma. Business StrategyRestructured company to focus o...

Cystic Fibrosis Trust

•        Cystic fibrosis is chronically misunderstood, kills thousands worldwide and is carried unknowingly in the genes of millions. It's often invisible to the naked eye yet destroys lives, stopping them short, inflicting hardship and distress on patients, their families and carers. Cystic fibrosis directly affects around 10,000 people in the UK. &b...


CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Instit...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

ACRO

Health outcomes aren't jeopardized when patients participate in randomized clinical trials of approved treatments, according to a new study. The results address misgivings some physicians have had about whether enrolling patients in a clinical trial might have a detrimental impact on their ability to receive individualized treatment. Conducted by a team led by Yale University's Dr. Cary P. Gross, ...

Cystic Fibrosis Foundation, Northern Ohio Chapter

The Northern Ohio Chapter of the Cystic Fibrosis Foundation works to help develop a means to control and cure cystic fibrosis and to improve the lives of those with the disease. The chapter serves 28 counties throughout Northern Ohio.

Ayala Pharmaceuticals

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. The company was founded in November 2017 with an experienced global management team and a strong investor base. The management bench recently expanded with the appointment of Andrea Vergar...

Longboat Clinical

Longboat is a clinical trials software company dedicated to generating better study outcomes by creating a complete support structure for site staff, patients, monitors, and study teams - where protocol compliance becomes easy and instinctive. In the complex world of clinical development, Longboat’s cloud-based site and patient engagement platform emp...

GlobalCare Clinical Trials, Ltd

GlobalCare Clinical Trials, Ltd, is the leading global provider of ambulant healthcare services for clinical trials to government agencies and the world’s biopharmaceutical and medical device companies engaged in all phases of product development. GlobalCare provides innovative, GCP-compliant services by conducting selected study visits in the home or...

Talee Bio, Inc.

Talee Bio is a development stage biopharmaceutical company focused on developing gene therapy products for the treatment of cystic fibrosis. The company is developing two inhaled gene therapy drug candidates to treat all cystic fibrosis patients: TL-101, a recombinant AAV-based gene therapy, and TL-102, a lentivirus gene therapy. The company was founded by...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

New Lung Associates

New Lung Associates is a pulmonary group of physicians leading the Lung Transplant Program and the Adult Cystic Fibrosis Program at Tampa General Hospital, a 988-bed acute care hospital in Tampa, Fla. The New Lung Associates team has specialized focus in the care of advanced lung diseases, cystic fibrosis, and lung transplantation. New Lung Associatesâ€...

Aranesp

Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis, and for the treatment of anemia in patients with nonmyeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.Important Product Safety InformationAranesp® is contraindicated in patien...

biospace med

biospace med has developed EOS ultra-low-dose 2D|3D, a new medical imaging modality that allows full-body 2D and 3D imaging of patients at very low irradiation doses. EOS is a novel technique and a global solution for orthopedic imaging that is now available in Europe and the USA. Based in Paris, the Company currently has approximately 40 employees, and ha...

AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals is a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. The Company’s lead candidate is tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, which AVEO is working to develop and commercialize in North America as a treatment for renal cell carcinoma (RC...

Conkwest, Inc.

Conkwest is an innovative immuno-oncology company that is developing and commercializing a portfolio of highly potent and selective cellular therapies for the treatment of cancers and serious viral infections. Conkwest’s products are based on its proprietary cancer-killing cell line Neukoplast™ (also known as NK-92), the only known cell line that ...

Imposter Research

IMPOSTER is the name of a medical research study of patients with muscle symptoms while taking cholesterol lowering therapies called statins. Several important findings from this study have been published and have raised questions about the safety of statin therapy for patients with muscle complaints. This website was developed to address those questions and to share what is known about statin mu...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and psoriasis. Shape has an ongoing Phase 1b clinical study in CTCL patients and has completed a Phase 1b clinical study in psoriasis patients. The development of SHP-141 is being supp...

Kite Pharma, Inc.

Kite Pharma, Inc. is a privately held development stage biotechnology company engaged in the design and development of cutting-edge immunotherapeutic products to treat different cancer indications. Kite's lead products include antigens associated with a wide variety of tumor types, and are initially being developed for the treatment of renal cell carcinoma...

BioDevelops Pharma GmbH

BioDevelops, an independent Austrian company, was initially founded back in 2002 and first concentrated on biomarker applications. Due to an opportunity to engage in the development of a clinical Phase II product with AOP Orphan Pharmaceuticals, the company changed its focus early in 2004 and entered the Cystic Fibrosis arena.Following successful turnaround, BioDevelops started its research operat...

Vitrolife AB (publ)

The fourth of the total of twelve patients included in the USA study for STEEN Solution™, and which enables sales approval in the important USA market, has now received a transplant. The first transplantation was carried out in September and four transplantations have thus now been carried out at four centres. A fifth centre, Duke University, has been ...

Annexon Biosciences

Annexon’s pipeline of novel therapies includes two clinical-stage product candidates, ANX005, a monoclonal antibody, and ANX007, a fragmented monoclonal antibody, as well as other compounds in preclinical development. ANX005 is currently in a Phase 1/2 study in patients with Guillain-Barre Syndrome (GBS). Annexon also plans to evaluate ANX005 in complement-mediated neurodegenerative disorder...


More From BioPortfolio on "A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations"

Quick Search

Corporate Database Quicklinks